Genmab — Share Issue/Capital Change 2013

Aug 21, 2013

Company Announcement

Copenhagen, Denmark; August 21, 2013 – Genmab A/S (OMX: GEN) will increase its
share capital by 157,878 shares as a consequence of the exercise of employee
warrants.

The increase is effected without any preemption rights for the existing
shareholders of the company or others. The shares are subscribed in cash at the
following price per share of nominally DKK 1: 250 shares at DKK 31.75, 35,000
shares at DKK 40.41, 50,000 shares at DKK 46.74, 250 shares at DKK 55.85, 2,000
shares at DKK 66.60, 2,450 shares at DKK 67.50 1,687 shares at DKK 68.65, 2,975
shares at DKK 86, 1,525 shares at DKK 89.50, 12,500 shares at DKK 97, 4,428
shares at DKK 101, 31,750 shares at DKK 114, 7,313 shares at DKK 116, 5,000
shares at DKK 129.75 and 750 shares at DKK 130. Proceeds to the company are
approx. DKK 11.4 million. The increase corresponds to approx. 0.31 % of the
company's share capital.

The increase includes the exercise of 50,000 warrants by President & CEO Jan
van de Winkel and 5,000 warrants by board member Burton G. Malkiel. This will
take Jan van de Winkel’s personal holding of shares in Genmab A/S from 445,000
to 495,000 shares. Following the warrant exercise Burton G. Malkiel’s personal
holding of shares in Genmab A/S will consist of 5,000 shares.

The new shares are ordinary shares without any special rights and are freely
transferable negotiable instruments. The new shares give rights to dividends
and other rights in relation to the company as of subscription, i.e. inter alia
full rights to dividends for the financial year 2013. The new shares will be
listed on NASDAQ OMX Copenhagen after registration with the Danish Business
Authority. Genmab A/S' current share capital amounts to DKK 51,052,818 and will
after the capital increase be DKK 51,210,696. The capital increase is expected
to be finalized shortly.

About Genmab A/S
Genmab is a publicly traded, international biotechnology company specializing
in the creation and development of differentiated human antibody therapeutics
for the treatment of cancer. Founded in 1999, the company’s first marketed
antibody, ofatumumab (Arzerra®), was approved to treat chronic lymphocytic
leukemia in patients who are refractory to fludarabine and alemtuzumab after
less than eight years in development. Genmab’s validated and next generation
antibody technologies are expected to provide a steady stream of future product
candidates. Partnering of innovative product candidates and technologies is a
key focus of Genmab’s strategy and the company has alliances with top tier
pharmaceutical and biotechnology companies. For more information visit
www.genmab.com.

Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations &
Communications
T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com

This Company Announcement contains forward looking statements. The words
“believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions
identify forward looking statements. Actual results or performance may differ
materially from any future results or performance expressed or implied by such
statements. The important factors that could cause our actual results or
performance to differ materially include, among others, risks associated with
pre-clinical and clinical development of products, uncertainties related to the
outcome and conduct of clinical trials including unforeseen safety issues,
uncertainties related to product manufacturing, the lack of market acceptance
of our products, our inability to manage growth, the competitive environment in
relation to our business area and markets, our inability to attract and retain
suitably qualified personnel, the unenforceability or lack of protection of our
patents and proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our products obsolete,
and other factors. For a further discussion of these risks, please refer to the
risk management sections in Genmab’s most recent financial reports, which are
available on www.genmab.com. Genmab does not undertake any obligation to update
or revise forward looking statements in this Company Announcement nor to
confirm such statements in relation to actual results, unless required by law.

Genmab A/S and its subsidiaries own the following trademarks: Genmab®; the
Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo™;
the DuoBody™ logo; HuMax®; HuMax-CD20®; DuoBody®, HexaBody(TM) and UniBody®.
Arzerra® is a registered trademark of GlaxoSmithKline.

Company Announcement no. 35
CVR no. 2102 3884

Genmab A/S
Bredgade 34E
1260 Copenhagen K
Denmark